Home
    • Plans Blog Contact
    biote Corp logo

    biote Corp

    BTMD
    Last price US$1.48
    Market cap US$71.7m
    12M price change -50.36%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Universal Health Services IncUHS Industry peer DaVita HealthCare Partners IncDVA Industry peer CHEMED CORPCHE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    biote Corp Overview

    Industry: Medical Care Facilities

    Sector: Healthcare

    biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irvine, Texas. biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and re Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for biote Corp into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 05, 2026

    Quarterly result summary

    Revenue was $44.2M (reported). Net loss was -$7.4M. Adjusted EBITDA was $5.6M.

    Revenue $44.2M reported
    Net loss -$7.4M reported
    Adjusted EBITDA $5.6M reported

    What changed

    • Revenue reported to $44.2M.

    Guidance / outlook

    we expect will drive improved financial performance in the second half.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 07, 2026 SEC filing 8-K Aug 05, 2026 SEC filing 10-Q May 11, 2026 SEC filing 8-K May 06, 2026 Earnings release Earnings release May 06, 2026 SEC filing 10-K Mar 13, 2026 SEC filing 8-K Mar 11, 2026 Earnings release Earnings release Mar 11, 2026 SEC filing 10-Q Nov 07, 2025 SEC filing 8-K Nov 05, 2025 Earnings release Earnings release Nov 05, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 0.00/5
    biote Corp earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Care Facilities industry , Universal Health Services Inc , DaVita HealthCare Partners Inc , CHEMED CORP are companies with high ratings.

    Return on Equity

    Score 3.99/5
    biote Corp stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    biote Corp BTMD US$71.7m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 4.06/5
    biote Corp commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    biote Corp BTMD US$71.7m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Care Facilities industry , Universal Health Services Inc , DaVita HealthCare Partners Inc , CHEMED CORP are companies with high ratings.

    Leverage

    Score 4.87/5
    biote Corp attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    biote Corp BTMD US$71.7m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    biote Corp logo

    biote Corp

    US$1.48

    US$71.7m

    1.32%

    -50.36%